

PRESS RELEASE



Stockholm March 9, 2017

Wilson Therapeutics to present at the Carnegie Healthcare Seminar 2017

Jonas Hansson, Chief Executive Officer, will present Wilson Therapeutics at the Carnegie Healthcare Seminar 2017 on March 16 in Stockholm. The presentation will be held at 8:20 CET at Carnegie's office at Regeringsgatan 56 in Stockholm, Sweden.

About Wilson Therapeutics

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics' lead product, WTX101, is initially being developed as a novel treatment for Wilson Disease and has been evaluated in a Phase 2 clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Visit www.wilsontherapeutics.com for more information.

For further information contact:

Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wtx.se

Wilson Therapeutics AB (publ)
Org nr 556893-0357
Kungsgatan 3
SE-111 43 Stockholm